These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22846417)

  • 21. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 23. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
    Rhodes C; Harris J; Sulston J; Spanswick C
    J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
    Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing treatments for age-related macular degeneration: safety, effectiveness and cost.
    Maguire MG
    LDI Issue Brief; 2012 Jun; 17(8):1-4. PubMed ID: 22754971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescribing bevacizumab off-label contravenes GMC advice.
    Kyle G
    BMJ; 2011 Nov; 343():d7131. PubMed ID: 22077076
    [No Abstract]   [Full Text] [Related]  

  • 27. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J
    JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
    [No Abstract]   [Full Text] [Related]  

  • 28. [Avastin and Lucentis for macular degeneration].
    Nau JY
    Rev Med Suisse; 2012 Aug; 8(351):1636-7. PubMed ID: 22988719
    [No Abstract]   [Full Text] [Related]  

  • 29. [Avastin-Lucentis: off-label and surroundings].
    Messori A
    Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. US ophthalmologists plead with drug regulator not to restrict access to Avastin.
    Cohen D
    BMJ; 2015 Mar; 350():h1266. PubMed ID: 25744537
    [No Abstract]   [Full Text] [Related]  

  • 31. Ranibizumab therapy for neovascular age-related macular degeneration.
    Folk JC; Stone EM
    N Engl J Med; 2010 Oct; 363(17):1648-55. PubMed ID: 20961248
    [No Abstract]   [Full Text] [Related]  

  • 32. By the way, doctor. My 78-year-old husband has wet macular degeneration. He is being treated with a drug called Avastin. Is that a good choice?
    Heier JS
    Harv Health Lett; 2010 May; 35(7):6. PubMed ID: 20583361
    [No Abstract]   [Full Text] [Related]  

  • 33. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.
    Messori A; Fadda V; Trippoli S
    Am J Ophthalmol; 2010 May; 149(5):867; author reply 867. PubMed ID: 20399931
    [No Abstract]   [Full Text] [Related]  

  • 34. [Vitreomacular traction in patients with exudative age-related macular degeneration].
    Abreu González R; Gallego-Pinazo R; Pérez Muñoz D; Pascual-Camps CI; Pérez Méndez L
    Arch Soc Esp Oftalmol; 2014 Jun; 89(6):255. PubMed ID: 24332686
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of cheaper eye drug would save billions, says US study.
    McCarthy M
    BMJ; 2014 Jun; 348():g4170. PubMed ID: 24950911
    [No Abstract]   [Full Text] [Related]  

  • 36. Should Avastin be used to treat age-related macular degeneration in the NHS?--Yes.
    Raftery J; Dent L
    Eye (Lond); 2009 Jun; 23(6):1247-9. PubMed ID: 19407834
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 38. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Donahue SP; Recchia F; Sternberg P
    Am J Ophthalmol; 2010 Aug; 150(2):287; author reply 287. PubMed ID: 20670740
    [No Abstract]   [Full Text] [Related]  

  • 39. Deal watch: Novartis eyes vision-enhancing therapy for macular degeneration.
    Cully M
    Nat Rev Drug Discov; 2014 Jul; 13(7):487. PubMed ID: 24981352
    [No Abstract]   [Full Text] [Related]  

  • 40. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.